{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:42:16Z","timestamp":1789429336714,"version":"build-2803163510"},"reference-count":214,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council","doi-asserted-by":"publisher","award":["19\/397"],"award-info":[{"award-number":["19\/397"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Limited antifungal treatment options and drug resistance require innovative approaches to effectively combat fungal infections. Combination therapy is a promising strategy that addresses these pressing issues by concurrently targeting multiple cellular sites. The drug targets usually selected for combination therapy are from different cellular pathways with the goals of increasing treatment options and reducing development of resistance. However, some circumstances can prevent the implementation of combination therapy in clinical practice. These could include the increased risk of adverse effects, drug interactions, and even the promotion of drug resistance. Furthermore, robust clinical evidence supporting the superiority of combination therapy over monotherapy is limited and underscores the need for further research. Despite these challenges, synergies detected with different antifungal classes, such as the azoles and echinocandins, suggest that treatment strategies can be optimized by better understanding the underlying mechanisms. This review provides an overview of multi-targeting combination strategies with a primary focus on Candidozyma auris infections.<\/jats:p>","DOI":"10.3390\/jof10100698","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:30:18Z","timestamp":1728286218000},"page":"698","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris"],"prefix":"10.3390","volume":"10","author":[{"given":"Stephanie","family":"Toepfer","sequence":"first","affiliation":[{"name":"Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand"},{"name":"Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail V.","family":"Keniya","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9073-2886","authenticated-orcid":false,"given":"Michaela","family":"Lackner","sequence":"additional","affiliation":[{"name":"Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-3480","authenticated-orcid":false,"given":"Brian C.","family":"Monk","sequence":"additional","affiliation":[{"name":"Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, October 10). WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/363682\/9789240060241-eng.pdf?sequence=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature12171","article-title":"Topographic diversity of fungal and bacterial communities in human skin","volume":"498","author":"Findley","year":"2013","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Dollive, S., Peterfreund, G.L., Sherrill-Mix, S., Bittinger, K., Sinha, R., Hoffmann, C., Nabel, C.S., Hill, D.A., Artis, D., and Bachman, M.A. (2012). A tool kit for quantifying eukaryotic rRNA gene sequences from human microbiome samples. Genome Biol., 13.","DOI":"10.1186\/gb-2012-13-7-r60"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ghannoum, M.A., Jurevic, R.J., Mukherjee, P.K., Cui, F., Sikaroodi, M., Naqvi, A., and Gillevet, P.M. (2010). Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000713"},{"key":"ref_5","first-page":"a019273","article-title":"The spectrum of fungi that infects humans","volume":"5","author":"Casadevall","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1473-3099(10)70218-8","article-title":"Emerging opportunistic yeast infections","volume":"11","author":"Miceli","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","unstructured":"World Health Organization (2023, April 22). Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease among Adults, Adolescents and Children Living with HIV. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240052178."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cleveland, A.A., Harrison, L.H., Farley, M.M., Hollick, R., Stein, B., Chiller, T.M., Lockhart, S.R., and Park, B.J. (2015). Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008\u20132013: Results from Population-Based Surveillance. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120452"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Papon, N., Courdavault, V., Clastre, M., and Bennett, R.J. (2013). Emerging and emerged pathogenic Candida species: Beyond the Candida albicans paradigm. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003550"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chowdhary, A., Sharma, C., and Meis, J.F. (2017). Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006290"},{"key":"ref_15","unstructured":"Centers for Disease Control and Prevention (2023, January 13). Candida auris: A Drug-Resitant Fungus That Spreads in Healthcare Facilities, Available online: https:\/\/www.cdc.gov\/candida-auris\/hcp\/laboratories\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/fungal\/candida-auris\/fact-sheets\/fact-sheet-lab-staff.html."},{"key":"ref_16","first-page":"e00029-17","article-title":"Candida auris: A Review of the Literature","volume":"31","author":"Taori","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","unstructured":"New Zealand Ministry of Health (2023, April 18). One Case of Candida auris Detected in New Zealand, Available online: https:\/\/www.health.govt.nz\/news-media\/news-items\/one-case-candida-auris-detected-new-zealand."},{"key":"ref_18","first-page":"19","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105901","DOI":"10.1016\/j.ijantimicag.2020.105901","article-title":"Colistin interacts synergistically with echinocandins against Candida auris","volume":"55","author":"Bidaud","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Caballero, U., Kim, S., Eraso, E., Quind\u00f3s, G., Vozmediano, V., Schmidt, S., and Jauregizar, N. (2021). In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040355"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10156-013-0639-0","article-title":"Combinatory effect of fluconazole and FDA-approved drugs against Candida albicans","volume":"19","author":"Kaneko","year":"2013","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e02063-19","DOI":"10.1128\/AAC.02063-19","article-title":"In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Schwarz, P., Bidaud, A.L., and Dannaoui, E. (2020). In vitro synergy of isavuconazole in combination with colistin against Candida auris. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-78588-5"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/21505594.2016.1196300","article-title":"Combinatorial strategies for combating invasive fungal infections","volume":"8","author":"Spitzer","year":"2017","journal-title":"Virulence"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","article-title":"Multi-target therapeutics: When the whole is greater than the sum of the parts","volume":"12","author":"Zimmermann","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.4155\/fmc-2016-0050","article-title":"Targeting efflux pumps to overcome antifungal drug resistance","volume":"8","author":"Holmes","year":"2016","journal-title":"Future Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fioriti, S., Brescini, L., Pallotta, F., Canovari, B., Morroni, G., and Barchiesi, F. (2022). Antifungal Combinations against Candida Species: From Bench to Bedside. J. Fungi, 8.","DOI":"10.3390\/jof8101077"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vandeputte, P., Ferrari, S., and Coste, A.T. (2012). Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol., 2012.","DOI":"10.1155\/2012\/713687"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"300","DOI":"10.15698\/mic2018.07.638","article-title":"Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms","volume":"5","author":"Sjollema","year":"2018","journal-title":"Microb. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2014Structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Chmielewska","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.1159746","article-title":"Outwitting Multidrug Resistance to Antifungals","volume":"321","author":"Monk","year":"2008","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Prasad, R. (2017). Using Yeast to Discover Inhibitors of Multidrug Efflux in Candida albicans. Candida albicans: Cellular and Molecular Biology, Springer International Publishing.","DOI":"10.1007\/978-3-319-50409-4"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s41429-018-0100-9","article-title":"Potential targets for the development of new antifungal drugs","volume":"71","author":"Su","year":"2018","journal-title":"J. Antibiot."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrmicro1179","article-title":"Evolution of antifungal-drug resistance: Mechanisms and pathogen fitness","volume":"3","author":"Anderson","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","article-title":"Antifungals","volume":"133","author":"Campoy","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/1568005023342344","article-title":"Genomic pathways to antifungal discovery","volume":"2","author":"Monk","year":"2002","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"a019703","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: Challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/EC.5.4.638-649.2006","article-title":"Conserved fungal genes as potential targets for broad-spectrum antifungal drug discovery","volume":"5","author":"Liu","year":"2006","journal-title":"Eukaryot. Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/0253-7613.62396","article-title":"Echinocandins: A ray of hope in antifungal drug therapy","volume":"42","author":"Grover","year":"2010","journal-title":"Indian J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1021\/bi962894z","article-title":"The formation of amphotericin B ion channels in lipid bilayers","volume":"36","author":"Fujii","year":"1997","journal-title":"Biochemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1085\/jgp.56.1.125","article-title":"The water and nonelectrolyte permeability induced in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B","volume":"56","author":"Holz","year":"1970","journal-title":"J. Gen. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1126\/science.6547247","article-title":"Allylamine derivatives: New class of synthetic antifungal agents inhibiting fungal squalene epoxidase","volume":"224","author":"Petranyi","year":"1984","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1039\/C3NP70070D","article-title":"Discovery and development of first in class antifungal caspofungin (CANCIDAS\u00ae)\u2014A case study","volume":"31","author":"Balkovec","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: The Newest Class of Antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/cid\/civ791","article-title":"Echinocandin Resistance in Candida","volume":"61","author":"Perlin","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: Mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/jac\/dkq073","article-title":"Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity","volume":"65","author":"Niimi","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Walker, L.A., Munro, C.A., de Bruijn, I., Lenardon, M.D., McKinnon, A., and Gow, N.A. (2008). Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000040"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12831","article-title":"Mechanisms of echinocandin antifungal drug resistance","volume":"1354","author":"Perlin","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2958.2012.08140.x","article-title":"Specific interactions between the Candida albicans ABC transporter Cdr1p ectodomain and a d-octapeptide derivative inhibitor: A surface active CaCdr1p-specific inhibitor","volume":"85","author":"Niimi","year":"2012","journal-title":"Mol. Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"ref_55","unstructured":"World Health Organization (2023, January 18). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2174\/0929867033368448","article-title":"Polyene macrolide antibiotics and their applications in human therapy","volume":"10","author":"Zotchev","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.bbamem.2013.03.021","article-title":"Quantifying membrane permeability of amphotericin B ion channels in single living cells","volume":"1828","author":"Yang","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1021\/acscentsci.1c00148","article-title":"Sterol Sponge Mechanism Is Conserved for Glycosylated Polyene Macrolides","volume":"7","author":"Guo","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: A comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"ref_61","first-page":"767","article-title":"Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model","volume":"137","author":"Mishra","year":"2013","journal-title":"Indian J. Med. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: An Overview of the Main Antifungal Agent Used to Treat Invasive Fungal Infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.apsb.2021.04.010","article-title":"Delivery strategies of amphotericin B for invasive fungal infections","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1139\/m77-058","article-title":"Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis","volume":"23","author":"Safe","year":"1977","journal-title":"Can. J. Microbiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/AAC.43.4.836","article-title":"High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance","volume":"43","author":"Yoon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e01131-18","DOI":"10.1128\/AAC.01131-18","article-title":"Heterologous Expression of Full-Length Lanosterol 14\u03b1-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery","volume":"62","author":"Keniya","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1749-6632.1988.tb40405.x","article-title":"Mechanism of action and biochemical selectivity of allylamine antimycotic agents","volume":"544","author":"Ryder","year":"1988","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/AAC.39.12.2738","article-title":"Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites","volume":"39","author":"Kovarik","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0190-9622(08)81263-7","article-title":"Current therapy of dermatophytosis","volume":"31","author":"Degreef","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","first-page":"402","article-title":"Guidelines for treatment of onychomycosis","volume":"148","author":"Roberts","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13318-014-0205-x","article-title":"A metoprolol-terbinafine combination induced bradycardia","volume":"40","author":"Bebawi","year":"2015","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.hlc.2013.11.012","article-title":"Interaction of terbinafine (anti-fungal agent) with perhexiline: A case report","volume":"23","author":"Sheikh","year":"2014","journal-title":"Heart Lung Circ."},{"key":"ref_73","first-page":"119","article-title":"Antifungal drug resistance in pathogenic fungi","volume":"36","author":"Dromer","year":"1998","journal-title":"Med. Mycol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/AAC.23.1.79","article-title":"Mechanisms of action of 5-fluorocytosine","volume":"23","author":"Waldorf","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1086\/514669","article-title":"Flucytosine monotherapy for cryptococcosis","volume":"27","author":"Hospenthal","year":"1998","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease","volume":"30","author":"Saag","year":"2000","journal-title":"Infect. Dis. Soc. Am. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1128\/AAC.00446-06","article-title":"Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans","volume":"51","author":"Schwarz","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: Practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"ref_81","first-page":"20499361231161387","article-title":"Flucytosine and its clinical usage","volume":"10","author":"Sigera","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Teixeira, M.M., Carvalho, D.T., Sousa, E., and Pinto, E. (2022). New Antifungal Agents with Azole Moieties. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111427"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Vardanyan, R., and Hruby, V. (2016). Antifungal Drugs. Synthesis of Best-Seller Drugs, Academic Press.","DOI":"10.1016\/B978-0-12-411492-0.00033-X"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1016\/j.bmcl.2014.05.068","article-title":"Design and optimization of highly-selective fungal CYP51 inhibitors","volume":"24","author":"Hoekstra","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_85","first-page":"DE01","article-title":"Molecular Mechanisms of Antifungal Drug Resistance in Candida Species","volume":"12","author":"Kumaramanickavel","year":"2018","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.11.2.382","article-title":"Clinical, cellular, and molecular factors that contribute to antifungal drug resistance","volume":"11","author":"White","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0021-9258(17)43458-2","article-title":"Yeast cytochrome P-450 catalyzing lanosterol 14 alpha-demethylation. I. Purification and spectral properties","volume":"259","author":"Yoshida","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbagen.2006.07.018","article-title":"Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms","volume":"1770","author":"Lepesheva","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e00570-17","DOI":"10.1128\/AAC.00570-17","article-title":"Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14\u03b1-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity","volume":"61","author":"Hargrove","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Monk, B.C., Sagatova, A.A., Hosseini, P., Ruma, Y.N., Wilson, R.K., and Keniya, M.V. (2020). Fungal Lanosterol 14\u03b1-demethylase: A target for next-generation antifungal design. Biochim. Biophys. Acta, 1868.","DOI":"10.1016\/j.bbapap.2019.02.008"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1128\/AAC.00925-15","article-title":"Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14\u03b1-Demethylase","volume":"59","author":"Sagatova","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/ajhp070532","article-title":"Posaconazole: A new oral antifungal agent with an expanded spectrum of activity","volume":"66","author":"Morris","year":"2009","journal-title":"AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.50.1.279-285.2006","article-title":"Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers","volume":"50","author":"Roos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-018-0513-7","article-title":"Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis","volume":"44","year":"2019","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1128\/AAC.48.8.3107-3111.2004","article-title":"In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates","volume":"48","author":"Mellado","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","article-title":"Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-021-00540-6","article-title":"Treatment Outcome with Fosravuconazole for Onychomycosis","volume":"186","author":"Shimoyama","year":"2021","journal-title":"Mycopathologia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/1346-8138.14607","article-title":"Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study","volume":"45","author":"Watanabe","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_100","unstructured":"DNDi (2024, June 28). A Randomized, Double Blind Phase II Proof-of-Concept Superiority Trial of Fosravuconazole 200 mg or 300 mg Weekly Dose Versus Itraconazole 400 mg Daily, All Three Arms in Combination with Surgery, in Patient with Eumycetoma in Sudan. Available online: http:\/\/dndi.org\/research-development\/portfolio\/fosravuconazole."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"ofaa016","DOI":"10.1093\/ofid\/ofaa016","article-title":"Hope on the Horizon: Novel Fungal Treatments in Development","volume":"7","author":"Rauseo","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"507","DOI":"10.12688\/f1000research.28327.1","article-title":"Novel antifungal agents in clinical trials","volume":"10","author":"Jacobs","year":"2021","journal-title":"F1000Research"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/21505594.2016.1257457","article-title":"New facets of antifungal therapy","volume":"8","author":"Chang","year":"2017","journal-title":"Virulence"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"McCarty, T.P., and Pappas, P.G. (2021). Antifungal Pipeline. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.732223"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.00731-11","article-title":"E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis","volume":"56","author":"Watanabe","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diagmicrobio.2011.05.001","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method","volume":"71","author":"Pfaller","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e02068-16","DOI":"10.1128\/AAC.02068-16","article-title":"Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis","volume":"61","author":"Wring","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e01102-17","DOI":"10.1128\/AAC.01102-17","article-title":"Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/jac\/dks466","article-title":"Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)","volume":"68","author":"Pfaller","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/AAC.02145-13","article-title":"Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates","volume":"58","author":"Paderu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e02396-16","DOI":"10.1128\/AAC.02396-16","article-title":"The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation","volume":"61","author":"Larkin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e00435-17","DOI":"10.1128\/AAC.00435-17","article-title":"In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris","volume":"61","author":"Berkow","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e00833-17","DOI":"10.1128\/AAC.00833-17","article-title":"De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance","volume":"61","author":"Perez","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1093\/jac\/dkw214","article-title":"Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates","volume":"71","author":"Pfaller","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diagmicrobio.2017.10.021","article-title":"Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris","volume":"90","author":"Berkow","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e02233-18","DOI":"10.1128\/AAC.02233-18","article-title":"The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates In Vitro and In Vivo Activity against Candida auris","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e01817-16","DOI":"10.1128\/AAC.01817-16","article-title":"Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds","volume":"61","author":"Schell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"myae032","DOI":"10.1093\/mmy\/myae032","article-title":"Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598","volume":"62","author":"Gu","year":"2024","journal-title":"Med. Mycol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: Mechanisms and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/524071","article-title":"Resistance to Antifungal Agents: Mechanisms and Clinical Impact","volume":"46","author":"Kanafani","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_126","unstructured":"Centers for Disease Control and Prevention (2023, February 13). Antimicrobial Resistance in Candida, Available online: https:\/\/www.cdc.gov\/candidiasis\/antimicrobial-resistance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/fungal\/diseases\/candidiasis\/antifungal-resistant.html."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"ofv163","DOI":"10.1093\/ofid\/ofv163","article-title":"Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data from a Large Multisite Population-Based Candidemia Surveillance Program, 2008\u20132014","volume":"2","author":"Vallabhaneni","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s15010-020-01475-8","article-title":"Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland","volume":"48","author":"Coste","year":"2020","journal-title":"Infection"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e00547-18","DOI":"10.1128\/mSphere.00547-18","article-title":"Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance","volume":"3","author":"Papp","year":"2018","journal-title":"mSphere"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ijantimicag.2017.05.012","article-title":"Molecular basis of antifungal drug resistance in yeasts","volume":"50","author":"Morio","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e00238-18","DOI":"10.1128\/AAC.00238-18","article-title":"Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris","volume":"62","author":"Kordalewska","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","article-title":"Candida auris Isolates Resistant to Three Classes of Antifungal Medications","volume":"69","author":"Ostrowsky","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_134","first-page":"1006","article-title":"In vitro interactions of azoles and echinocandins against clinical strains of Aspergillus flavus","volume":"56","author":"Denardi","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Rodrigues, C.F., Alves, D.F., and Henriques, M. (2018). Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms. Microorganisms, 6.","DOI":"10.3390\/microorganisms6040123"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Keniya, M.V., Fleischer, E., Klinger, A., Cannon, R.D., and Monk, B.C. (2015). Inhibitors of the Candida albicans Major Facilitator Superfamily Transporter Mdr1p Responsible for Fluconazole Resistance. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126350"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_138","first-page":"331","article-title":"The search for synergy: A critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Tang, J., Wennerberg, K., and Aittokallio, T. (2015). What is synergy? The Saariselk\u00e4 agreement revisited. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00181"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","article-title":"Combination antifungal therapy","volume":"48","author":"Johnson","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Lederer, S., Dijkstra, T.M.H., and Heskes, T. (2019). Additive Dose Response Models: Defining Synergy. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01384"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/AAC.45.12.3366-3374.2001","article-title":"Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters","volume":"45","author":"Nakamura","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/jac\/dkh456","article-title":"Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance","volume":"54","author":"Niimi","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_146","unstructured":"National Institutes of Health Office of AIDS Research (2023, August 08). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combination-regimens."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple Combination Therapy with 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S1473-3099(23)00731-4","article-title":"Global guideline for the diagnosis and management of cryptococcosis: An initiative of the ECMM and ISHAM in cooperation with the ASM","volume":"24","author":"Chang","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41572-023-00472-z","article-title":"Cryptococcal meningitis","volume":"9","author":"Tugume","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination Antifungal Therapy for Invasive Aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: A randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Stenkiewicz-Witeska, J.S., and Ene, I.V. (2023). Azole potentiation in Candida species. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011583"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"myac008","DOI":"10.1093\/mmy\/myac008","article-title":"Emerging and future strategies in the management of recalcitrant Candida auris","volume":"60","author":"Bandara","year":"2022","journal-title":"Med Mycol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apm.13336","article-title":"Azole resistance in Candida auris: Mechanisms and combinatorial therapy","volume":"131","author":"Jangir","year":"2023","journal-title":"Apmis"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/CMR.00051-08","article-title":"Efflux-mediated antifungal drug resistance","volume":"22","author":"Cannon","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6976.1998.tb00358.x","article-title":"ATP-binding-cassette (ABC) transport systems: Functional and structural aspects of the ATP-hydrolyzing subunits\/domains","volume":"22","author":"Schneider","year":"1998","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrm2646","article-title":"ABC transporters: The power to change","volume":"10","author":"Rees","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_160","first-page":"3","article-title":"Complete inventory of ABC proteins in human pathogenic yeast, Candida albicans","volume":"9","author":"Gaur","year":"2005","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.cb.08.110192.000435","article-title":"ABC transporters: From microorganisms to man","volume":"8","author":"Higgins","year":"1992","journal-title":"Annu. Rev. Cell Biol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0076-6879(98)92012-2","article-title":"Saccharomyces cerevisiae ABC proteins and their relevance to human health and disease","volume":"292","author":"Taglicht","year":"1998","journal-title":"Methods Enzymol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/pro.650","article-title":"Structural consequences of ATP hydrolysis on the ABC transporter NBD dimer: Molecular dynamics studies of HlyB","volume":"20","author":"Damas","year":"2011","journal-title":"Protein Sci. A Publ. Protein Soc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/j.1460-2075.1982.tb01276.x","article-title":"Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold","volume":"1","author":"Walker","year":"1982","journal-title":"Embo J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"41303","DOI":"10.1074\/jbc.C200484200","article-title":"The \u201cLSGGQ\u201d motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence","volume":"277","author":"Loo","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.micro.61.080706.093329","article-title":"Ins and outs of major facilitator superfamily antiporters","volume":"62","author":"Law","year":"2008","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"fow043","DOI":"10.1093\/femsyr\/fow043","article-title":"MFS transporters of Candida species and their role in clinical drug resistance","volume":"16","author":"Redhu","year":"2016","journal-title":"FEMS Yeast Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/MMBR.62.1.1-34.1998","article-title":"Major Facilitator Superfamily","volume":"62","author":"Pao","year":"1998","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1574-6976.1997.tb00347.x","article-title":"Classification of all putative permeases and other membrane plurispanners of the major facilitator superfamily encoded by the complete genome of Saccharomyces cerevisiae","volume":"21","author":"Nelissen","year":"1997","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/scdb.2000.0246","article-title":"Phylogeny of multidrug transporters","volume":"12","author":"Saier","year":"2001","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Gaur, M., Puri, N., Manoharlal, R., Rai, V., Mukhopadhayay, G., Choudhury, D., and Prasad, R. (2008). MFS transportome of the human pathogenic yeast Candida albicans. BMC Genom., 9.","DOI":"10.1186\/1471-2164-9-579"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1046\/j.1365-2958.2000.01899.x","article-title":"Targeted gene disruption in Candida albicans wild-type strains: The role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates","volume":"36","author":"Wirsching","year":"2000","journal-title":"Mol. Microbiol."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Toepfer, S., Lackner, M., Keniya, M.V., and Monk, B.C. (2023). Functional Expression of Recombinant Candida auris Proteins in Saccharomyces cerevisiae Enables Azole Susceptibility Evaluation and Drug Discovery. J. Fungi, 9.","DOI":"10.3390\/jof9020168"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.48.4.1256-1271.2004","article-title":"Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative","volume":"48","author":"Niimi","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1574-6968.2011.02490.x","article-title":"A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model","volume":"328","author":"Hayama","year":"2012","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Yong, J., Zu, R., Huang, X., Ge, Y., and Li, Y. (2020). Synergistic Effect of Berberine Hydrochloride and Fluconazole Against Candida albicans Resistant Isolates. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01498"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/AAC.05706-11","article-title":"The Monoamine Oxidase A Inhibitor Clorgyline Is a Broad-Spectrum Inhibitor of Fungal ABC and MFS Transporter Efflux Pump Activities Which Reverses the Azole Resistance of Candida albicans and Candida glabrata Clinical Isolates","volume":"56","author":"Holmes","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Toepfer, S., Lackner, M., Keniya, M.V., Zenz, L.M., Friemert, M., Bracher, F., and Monk, B.C. (2023). Clorgyline Analogs Synergize with Azoles against Drug Efflux in Candida auris. J. Fungi, 9.","DOI":"10.3390\/jof9060663"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijantimicag.2017.09.012","article-title":"Gentamicin synergises with azoles against drug-resistant Candida albicans","volume":"51","author":"Lu","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nature06836","article-title":"A nuclear receptor-like pathway regulating multidrug resistance in fungi","volume":"452","author":"Thakur","year":"2008","journal-title":"Nature"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1101\/gad.12.20.3195","article-title":"SXR, a novel steroid and xenobiotic-sensing nuclear receptor","volume":"12","author":"Blumberg","year":"1998","journal-title":"Genes Dev."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","article-title":"Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction","volume":"95","author":"Bertilsson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1093\/nar\/gkn349","article-title":"Comparative genomics supports a deep evolutionary origin for the large, four-module transcriptional mediator complex","volume":"36","author":"Bourbon","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Sato, N., Suetaka, S., Hayashi, Y., and Arai, M. (2023). Rational peptide design for inhibition of the KIX\u2013MLL interaction. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32848-2"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/10408419409114555","article-title":"Fungal Plasma Membrane Proton Pumps as Promising New Antifungal Targets","volume":"20","author":"Monk","year":"1994","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0005-2736(95)00133-N","article-title":"The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole","volume":"1239","author":"Monk","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0005-2736(97)00028-X","article-title":"Exploring an antifungal target in the plasma membrane H+-ATPase of fungi","volume":"1326","author":"Monk","year":"1997","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Biomembr."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/AAC.49.1.57-70.2005","article-title":"Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance","volume":"49","author":"Monk","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e01056-17","DOI":"10.1128\/AAC.01056-17","article-title":"In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris","volume":"61","author":"Fakhim","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e02031-20","DOI":"10.1128\/AAC.02031-20","article-title":"Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program","volume":"65","author":"Pfaller","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"13007","DOI":"10.1021\/acs.jmedchem.3c00942","article-title":"Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_192","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"13838","DOI":"10.1021\/acs.jmedchem.3c01372","article-title":"Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1021\/acs.jmedchem.4c00710","article-title":"Construction and Activity Evaluation of Novel Bifunctional Inhibitors and a COF Carrier Based on a Fungal Infection Microenvironment","volume":"67","author":"Yu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41564-024-01662-5","article-title":"A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens","volume":"9","author":"Zhou","year":"2024","journal-title":"Nat. Microbiol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ijantimicag.2018.08.016","article-title":"Synergistic interactions of sulfamethoxazole and azole antifungal drugs against emerging multidrug-resistant Candida auris","volume":"52","author":"Eldesouky","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2215\/CJN.08140718","article-title":"Clinical Pharmacology of Antibiotics","volume":"14","author":"Eyler","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e00684-20","DOI":"10.1128\/AAC.00684-20","article-title":"Potent Synergistic Interactions between Lopinavir and Azole Antifungal Drugs against Emerging Multidrug-Resistant Candida auris","volume":"65","author":"Eldesouky","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"106906","DOI":"10.1016\/j.ijantimicag.2023.106906","article-title":"Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis","volume":"62","author":"Salama","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Sun, Y., Tan, L., Yao, Z., Gao, L., Yang, J., and Zeng, T. (2022). In Vitro and In Vivo Interactions of TOR Inhibitor AZD8055 and Azoles against Pathogenic Fungi. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02007-21"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In Vitro and In Vivo Antitumor Activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/21505594.2020.1838741","article-title":"Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs","volume":"11","author":"Eldesouky","year":"2020","journal-title":"Virulence"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Eldesouky, H.E., Salama, E.A., Hazbun, T.R., Mayhoub, A.S., and Seleem, M.N. (2020). Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-62976-y"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e00449-20","DOI":"10.1128\/mBio.00449-20","article-title":"Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture","volume":"11","author":"Fisher","year":"2020","journal-title":"mBio"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1128\/AAC.01092-06","article-title":"A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations","volume":"51","author":"Mellado","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgar.2015.01.005","article-title":"Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?","volume":"3","author":"Sharma","year":"2015","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"Camps","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"myad069","DOI":"10.1093\/mmy\/myad069","article-title":"In vitro combination of antifungal drugs with tacrolimus (FK506) holds promise against clinical Candida species, including Candida auris","volume":"61","author":"Khodavaisy","year":"2023","journal-title":"Med. Mycol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","article-title":"A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs","volume":"42","author":"Hertogs","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_212","first-page":"E2874","article-title":"Imperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance","volume":"112","author":"Hill","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"7722","DOI":"10.1038\/s41467-024-52107-w","article-title":"Cryo-EM structures of Candida albicans Cdr1 reveal azole-substrate recognition and inhibitor blocking mechanisms","volume":"15","author":"Peng","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/10\/698\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:05Z","timestamp":1760112725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/10\/698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":214,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jof10100698"],"URL":"https:\/\/doi.org\/10.3390\/jof10100698","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]}}}